Mount Yale Investment Advisors LLC Purchases 26 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Mount Yale Investment Advisors LLC raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 484 shares of the medical equipment provider’s stock after acquiring an additional 26 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in Intuitive Surgical were worth $253,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Mirador Capital Partners LP raised its holdings in Intuitive Surgical by 1.4% during the third quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock valued at $1,732,000 after buying an additional 50 shares in the last quarter. M.E. Allison & CO. Inc. bought a new stake in Intuitive Surgical during the fourth quarter worth approximately $449,000. Seilern Investment Management Ltd acquired a new position in Intuitive Surgical during the fourth quarter valued at approximately $82,517,000. Exome Asset Management LLC raised its position in shares of Intuitive Surgical by 16.8% in the third quarter. Exome Asset Management LLC now owns 7,427 shares of the medical equipment provider’s stock valued at $3,649,000 after purchasing an additional 1,069 shares during the period. Finally, Consolidated Planning Corp boosted its holdings in shares of Intuitive Surgical by 17.4% during the 3rd quarter. Consolidated Planning Corp now owns 8,099 shares of the medical equipment provider’s stock worth $3,979,000 after buying an additional 1,198 shares during the period. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Stock Performance

ISRG opened at $572.71 on Thursday. Intuitive Surgical, Inc. has a twelve month low of $364.17 and a twelve month high of $616.00. The firm has a market cap of $203.99 billion, a PE ratio of 92.08, a price-to-earnings-growth ratio of 5.19 and a beta of 1.39. The firm’s fifty day moving average is $548.70 and its two-hundred day moving average is $507.04.

Insiders Place Their Bets

In related news, Director Amal M. Johnson sold 4,635 shares of the stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the completion of the transaction, the director now directly owns 12,275 shares in the company, valued at approximately $6,955,015. This trade represents a 27.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jamie Samath sold 94 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $571.11, for a total transaction of $53,684.34. Following the transaction, the chief financial officer now directly owns 2,630 shares of the company’s stock, valued at $1,502,019.30. This represents a 3.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,843 shares of company stock worth $15,357,560. Corporate insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Royal Bank of Canada raised their price target on shares of Intuitive Surgical from $611.00 to $641.00 in a research report on Monday. Jefferies Financial Group increased their price target on shares of Intuitive Surgical from $475.00 to $575.00 in a research report on Monday. Evercore ISI lifted their price objective on Intuitive Surgical from $490.00 to $530.00 in a report on Monday. Citigroup increased their target price on Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Finally, Raymond James upped their price target on Intuitive Surgical from $560.00 to $688.00 and gave the company an “outperform” rating in a research report on Friday, January 24th. One analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average target price of $613.10.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.